Tildrakizumab also significantly improved skin symptoms and quality of life in patients with moderate to severe plaque psoriasis after 28 weeks in a real-world setting and with a safety profile consistent with randomized phase III clinical trials1,2
Almirall has shown for the first time that the wellbeing of patients with moderate to severe plaque psoriasis at baseline was comparable to the level of wellbeing found in other diseases3 such as breast cancer4
Preliminary results of the POSITIVE study demonstrate the company's commitment to addressing unmet needs in the treatment of patients with psoriasis